Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiovasc Res ; 99(1): 137-45, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23519265

ABSTRACT

AIMS: L5 is the most negatively charged subfraction of human low-density lipoprotein (LDL) and is the only subfraction of LDL capable of inducing apoptosis in cultured vascular endothelial cells (ECs) by inhibiting fibroblast growth factor-2 (FGF2) transcription. We examined whether plasma L5 levels are elevated in patients with ST-segment elevation myocardial infarction (STEMI) and whether aspirin provides epigenetic protection of human coronary artery ECs (HCAECs) exposed to L5. METHODS AND RESULTS: Plasma L5 levels were compared between patients with STEMI (n = 10) and control subjects with chest pain syndrome but a normal coronary arteriogram (n = 5). L5 was isolated from the plasma of STEMI patients and control subjects, and apoptosis, FGF2 expression, and FGF2 promoter methylation were examined in HCAECs treated with L5 and aspirin. Plasma L5 levels were significantly higher in STEMI patients than in control subjects (P < 0.001). Treatment of HCAECs with L5 resulted in reduced survival and FGF2 expression and increased CpG methylation of the FGF2 promoter. Co-treatment of HCAECs with L5 and a physiologically relevant, low concentration of aspirin (0.2 mM) attenuated the adverse effects of L5 on HCAEC survival, FGF2 expression, and FGF2 promoter methylation. In contrast, high concentrations of aspirin (≥1.0 mM) accentuated the effects of L5. CONCLUSIONS: Our results show that L5 levels are significantly increased in STEMI patients. Furthermore, L5 impairs HCAEC function through CpG methylation of the FGF2 promoter, which is suppressed in the presence of low-concentration aspirin. Our results provide evidence of a novel mechanism of aspirin in the prevention of MI.


Subject(s)
Apoptosis/drug effects , Aspirin/pharmacology , Cardiovascular Agents/pharmacology , Coronary Artery Disease/drug therapy , Coronary Vessels/drug effects , Endothelial Cells/drug effects , Epigenesis, Genetic/drug effects , Lipoproteins, LDL/blood , Myocardial Infarction/drug therapy , Aged , Base Sequence , Case-Control Studies , Cell Survival/drug effects , Cells, Cultured , Coronary Artery Disease/blood , Coronary Artery Disease/genetics , Coronary Artery Disease/pathology , Coronary Vessels/metabolism , Coronary Vessels/pathology , CpG Islands/drug effects , Cytoprotection , DNA Methylation/drug effects , Dose-Response Relationship, Drug , Endocytosis/drug effects , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , Humans , Male , Middle Aged , Molecular Sequence Data , Myocardial Infarction/blood , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Promoter Regions, Genetic/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Scavenger Receptors, Class E/genetics , Scavenger Receptors, Class E/metabolism , Transfection , Up-Regulation
2.
Circ Res ; 102(8): 933-41, 2008 Apr 25.
Article in English | MEDLINE | ID: mdl-18309099

ABSTRACT

Homocysteine (Hcy) contributes to atherogenesis and angiostasis by altering the phenotype of arterial endothelial cells (ECs). The present study was aimed at elucidating potential mechanisms by which Hcy can slow EC proliferation and induce EC apoptosis, thereby disrupting endothelial integrity. Given the strong mitogenic and antiapoptotic properties of fibroblast growth factor (FGF)2, we examined whether Hcy can modulate its expression. In cultured human coronary and bovine aortic ECs, Hcy exerted time- and concentration-dependent (0 to 500 micromol/L) reduction of the mRNA and protein levels of FGF2, whereas vascular endothelial growth factor expression was not affected until Hcy reached a proapoptotic 500 micromol/L. By testing a panel of signal transduction inhibitors, we found that the Hcy-induced downregulation of FGF2 was specifically attenuated by pertussis toxin, an inhibitor of Gi protein signaling. Hcy induced cell cycle arrest at the G(1)/S transition and increased TUNEL-positive apoptotic cells in a graded manner. These effects were effectively counteracted by exogenous FGF2. Reporter gene assays showed that Hcy downregulated FGF2 by transcriptional repression of the gene promoter encompassed in a CpG dinucleotide-rich island. This region was heavily methylated at the cytosine residues by Hcy despite decreased methylation potential (S-adenosylmethionine to S-adenosylhomocysteine ratio). Normal levels of FGF2 transcription were restored to ECs simultaneously exposed to Hcy and 5-aza-deoxycytidine. We conclude that homocysteine disrupts the growth and survival of ECs through a G protein-mediated pathway associated with altered promoter DNA methylation and the transcriptional repression of FGF2.


Subject(s)
Arteries/cytology , Cell Proliferation/drug effects , Endothelial Cells/cytology , Fibroblast Growth Factor 2/genetics , GTP-Binding Proteins/metabolism , Homocystine/pharmacology , Animals , Cattle , DNA Methylation , Down-Regulation/drug effects , Transcription, Genetic
3.
J Lipid Res ; 45(11): 2116-22, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15314101

ABSTRACT

Hypercholesterolemic human LDL contains oxidized subfractions that have atherogenic properties. Paradoxically, atherosclerosis incidence is low in patients with primary biliary cirrhosis (PBC), a disease characterized by marked increases in plasma LDL, including the LDL subfraction lipoprotein-X (Lp-X). To investigate the mechanisms underlying this paradox, we first examined the propensity to oxidation of unfractionated LDL isolated from PBC patients. After prolonged incubation with copper, PBC-LDL failed to increase the oxidation index or electrophoretic mobility noted in control LDL. An admixture of PBC-LDL or Lp-X with control LDL prevented oxidation of the latter in a dose-dependent manner. PBC-LDL was also noncompetitive against copper-oxidized LDL (oxLDL) for binding with a murine monoclonal anti-oxLDL antibody in a competitive ELISA. OxLDL exerts its proapoptotic and antiangiogenic effects in part by inhibiting fibroblast growth factor 2 (FGF2) expression. Preincubation of oxLDL with PBC-LDL, but not control LDL, attenuated the inhibitory effects of oxLDL on FGF2 expression in cultured bovine aortic endothelial cells (ECs). The antioxidant and prosurvival properties of PBC-LDL diminished after the patients underwent orthotopic liver transplantation. These results suggest that Lp-X reduces LDL atherogenicity by preventing LDL oxidation to protect EC integrity in the presence of hypercholesterolemia. They also suggest that altering LDL composition may be as important as reducing LDL concentration in preventing or treating atherosclerosis.


Subject(s)
Lipoprotein-X/metabolism , Liver Cirrhosis, Biliary/metabolism , Oxygen/metabolism , Animals , Aorta/cytology , Apoptosis , Cattle , Cells, Cultured , Chromatography, Gel , Down-Regulation , Electrophoresis, Agar Gel , Endothelium, Vascular/cytology , Enzyme-Linked Immunosorbent Assay , Fibroblast Growth Factor 2/metabolism , History, 20th Century , Ligands , Lipoproteins, LDL/metabolism , Peptides/chemistry , RNA, Messenger/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...